Condition: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · HER2-positive Breast Cancer · Breast Cancer · Sponsor: University of Chicago
Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.
This description comes directly from the study's public registry record.
Olufunmilayo Olopade · (773) 702-1632 · folopade@medicine.bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| Lagos State University Teaching Hospital | Ikeja, Lagos, Nigeria | Recruiting |
| Lagos University Teaching Hospital | Yaba, Lagos, Nigeria | Recruiting |
| Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC) | Ile-Ife, Osun State, Nigeria | Recruiting |
| University of Ibadan Hospital | Ibadan, Oyo State, Nigeria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06348134